Monthly Archives: March 2012

Jessica Capshaw Talks Twitter Photo War With 'Grey's Anatomy' Co-Star Patrick Dempsey

Posted on by

"Grey's Anatomy" returns with an all new episode this Thursday on ABC, but during her visit to Access Hollywood Live on Tuesday, actress Jessica Capshaw revealed there is some Internet-related drama brewing behind the scenes too.

According to the actress, who plays Dr. Arizona Robbins, she and Patrick Dempsey are involved in an amusing Twitter photo war.

PLAY IT NOW: Would Patrick Dempsey Like To See Katherine Heigl Back On Greys Anatomy?

"We got into a Twitter pic war, where literally he was wielding his iPhone like it was a weapon," Jessica smiled as she told Billy Bush and Kit Hoover what's been going on with Patrick.

Jessica explained that Patrick, who recently joined Twitter, has become fond of posting photos of his cast mates, including her, in less than perfect poses.

VIEW THE PHOTOS: The Lovely Ladies Of Primetime Television

"Patrick most likes to take pictures of me in compromising positions," Jessica explained of the amusing way they've been spending their down time on set. "[Like] when you're in the middle of taking a bite of a muffin, making a sun [squinting] face, doing something that's just not attractive."

Now, for all of Twitter to see, there are a host of unapproved photos circulating of Jessica and some of her fellow "Grey's" co-stars.

"He doesn't ask us [before posting]. We live in this world where it's like, it'd be nice if someone said, 'Hey! I just took this picture, I'm gonna Tweet it now," she explained.

VIEW THE PHOTOS: Primetime Hunks

See the original post:
Jessica Capshaw Talks Twitter Photo War With 'Grey's Anatomy' Co-Star Patrick Dempsey

Two ECU grad programs ranked

Posted on by

Two graduate programs at East Carolina University have been ranked among the best in the nation according to an annual list from U.S. News & World Report.

The rehabilitation counseling program and the Brody School of Medicine were included in the magazine's 2013 listing of the best professional and graduate schools released today.

The rehabilitation counseling program in the College of Allied Health Sciences is ranked the 13th.

"Our graduates are in high demand in substance abuse, mental health and other rehabilitation settings," said Dr. Lloyd Goodwin, professor and interim chair of the Department of Rehabilitation Studies at ECU.

"Student interns are almost always offered jobs at the end of their internship and often before completion of their internship. It is rare for a graduate to not be offered a position within one month of graduation."

The Brody School of Medicine tied for 31st overall among primary care schools this year. ECU also sent the seventh-highest percentage of its graduates, 49.6 percent, into primary care residencies between 2009 and 2011. U.S. News defines primary care as family medicine, pediatrics and internal medicine.

"We are glad to be included among some very fine and well-established schools from across the country," said Dr. Paul Cunningham, dean of the medical school. "We will continue to pursue our mission to serve the citizens of North Carolina with passion and purpose."

The U.S. News guidebook of U.S. professional and graduate schools will be available on newsstands April 3.

Continue reading here:
Two ECU grad programs ranked

Cannabis Science, Inc. Begins Pre-Production of Groundbreaking Cannabis Television Documentary

Posted on by

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--

Cannabis Science, Inc. (OTCBB:CBIS.OB - News), a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is excited to be embarking on a medical marijuana documentary project. Pre-production of this groundbreaking educational film is currently underway.

Many documentaries about marijuana have been made, typically focusing on getting high or the medicinal effects and benefits. Cannabis Science will be first documentary to focus on the science behind medicinal cannabis, including untangling the history of marijuanas reputation, the improvement it can bring to peoples daily lives, and what breakthroughs could be on the horizon for this emerging industry.

Modern science supports a long list of illnesses that cannabis can treat: Multiple Sclerosis, Cancer, Arthritis, HIV/Aids, Asthma, Alzheimer's Disease, Anti-aging, Auto Immune Disease, brain trauma (closed head injury), Crohn's Disease, chronic pain management, Diabetes, digestive illnesses, Gastro Intestinal Reflux Disease (GERD), high blood pressure, Glaucoma, Influenza, Methicillin-Resistant Staphylococcus Aureus (MRSA), Post Traumatic Stress Disorder (PTSD), Tourette Syndrome, and Irritable Bowel Syndrome (IBS), etc. The science gives a foundation for understanding the broad spectrum of benefits that can be achieved by increasing the cannabinoid activity in people suffering from so many illnesses.

Part of the science that will be explored are the various forms marijuana can take as a medication, including edibles, pills, liquids, and strips that dissolve on the tongue. The documentary will investigate how these forms are processed in the body and can reverse or minimized the effects of disease. Cannabis Science is first and foremost a patient orientated company. Therefore, patients will be interviewed, giving the audience a glimpse at the real, positive benefits the medicine provides for those with chronic illness, as opposed to the prevailing and false belief that marijuana is addictive and even harmful.

Other documentaries showcase marijuana culture, likening it to the popular view of the 1960s and marijuana use running rampant among the hippie population. Cannabis Sciences documentary, however, will show cannabis in a positive light and demonstrate that what has been, and is, taught by prohibitionists is false, and ignores modern science, history, and the voice of patients. The documentary will also focus on the co-founders of Cannabis Science, how the company is working to target critical illnesses, conducting much needed research, and is developing cannabis-based medications. The audience will hear the views of doctors who have discovered for themselves through treating patients the amazing benefits that cannabis based medicines can provide for their patients.

While the main focus of the documentary is not political, learning the truth about the science of cannabinoids will educate the public on the damage caused by prohibition. Patients whose circumstances could have drastically improved and who could have reduced the severity of their illnesses much earlier from medical marijuana will be interviewed. The film will explore the reasons behind the delay in world governments opening up to the idea that medical marijuana is a beneficial reality.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Read more:
Cannabis Science, Inc. Begins Pre-Production of Groundbreaking Cannabis Television Documentary

StemCells, Inc. Reports Fourth Quarter and Year End 2011 Financial Results and Provides Business Update

Posted on by

NEWARK, Calif., March 13, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM - News), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the fourth quarter and year ended December 31, 2011 and provided a business update.

"The StemCells team made significant progress in 2011 with regard to two critical goals for the Company, namely accelerating and broadening our HuCNS-SC neural stem cell clinical trial agenda for diseases of, and injuries to, the central nervous system, while at the same time reducing our operating cash burn. We are now uniquely positioned as the only stem cell company pursuing clinical trials for disorders of all three organs of the CNS, the brain, spinal cord and eye," said Martin McGlynn, President and CEO of StemCells, Inc. "We have strong preclinical data underlying all our clinical trials, much of which has already been published in peer-reviewed journals, but we realize that the true test of our proprietary cell-based technology will be in the clinic. In this regard, I am pleased to confirm StemCells remains on track to report safety and efficacy data from our recently completed Phase I Pelizeaus-Merzbacher disease trial at the European Leukodystrophy Association meeting to be held in Paris, March 31-April 1. We are confident that executing our clinical trial agenda, while controlling our cash burn, is the best way to build lasting shareholder value."

Fourth Quarter and Recent Business Highlights

Therapeutic Product Development

Tools and Technologies Programs

Other Business Activities

Fourth Quarter 2011 Financial Results

For the fourth quarter of 2011, the Company reported a net loss of $7,212,000, or $(0.47) per share, compared with a net loss of $8,957,000, or $(0.70) per share, for the fourth quarter of 2010. Loss from operations in the fourth quarter of 2011 was $7,313,000, which was 5% lower when compared to the $7,706,000 loss from operations in the fourth quarter of 2010. Included in net loss and loss from operations in the fourth quarter of 2011 is a charge of $655,000 for the write-off of an acquired intangible asset.

Total revenue during the fourth quarter of 2011 was $541,000, compared to $699,000 in the same period of 2010. The decrease of 23% from 2010 to 2011 was due to both lower product sales and lower licensing and grant revenues. Total revenues in the fourth quarter of 2010 were higher due to a particularly strong quarter in our SC Proven business as well as the receipt of a milestone payment under a licensing agreement of approximately $438,000 in 2010.

Total operating expenses in the fourth quarter of 2011 were $7,807,000, compared to $8,341,000 in the fourth quarter of 2010. Excluding the impairment of the intangible asset, which is included as an operating expense, total operating expenses in the fourth quarter of 2011 were $7,152,000, or 14% lower than the same period in 2010. In the fourth quarter of 2011, research and development expenses totaled $4,834,000, or 18% less than in the same period of 2010, while selling, general and administrative expenses totaled $2,290,000, or 8% lower. The significant reduction in operating expenses was primarily attributable to the Company's cost containment efforts, including the reduction in force effected in May 2011.

See original here:
StemCells, Inc. Reports Fourth Quarter and Year End 2011 Financial Results and Provides Business Update

Kellogg’s-sponsored Nutrition talks at KMS Skolasport

Posted on by

KMS Skolasport is organising talks on nutrition and healthy breakfast for parents and adults at its various sports complexes in Malta. The talks are sponsored by Kelloggs, the worlds leading provider of breakfast cereals, and official sponsor of KMS Skolasport for the past 12 years.

The talks on nutrition will be conducted by Jeremy Ellul, state registered nutritionist and physiotherapist. He will address the importance of a healthy balanced diet, and the benefits of breakfast cereals and snacking. The talks will be conducted in Maltese and each talk will be followed by a question and answer session.

In line with its commitment to reach as many parents as possible, KMS Skolasport is holding two talks on Saturday mornings in five different localities. The first two talks will be held on Saturday 17th March 2012 in the Lecture Room at Maria Regina College in Mosta starting at 9.00am till 10am and a repeat session at 10.30am till 11.30am.

The talks will be repeated on 24th March at St Ignatius College Tal-Handaq Sports Complex, on the 14th April at KMS Tal-Qroqq Sports Complex, on 21st April at St Benedicts Sports Complex in Kirkop, and on 28th April at Cottonera Sports Complex.

Since the year 2000, Kelloggs has sponsored KMS Skolasport to promote sport and physical activity among the young Maltese generations. Kelloggs and KMS share the same commitment and encourage physical activity from a young age and caring for the Maltese community healthy lifestyle.

As a responsible corporate company, Kelloggs invests in the communities where it operates, such as Malta, said Tony Papadoukakis, Kelloggs Market Development Manager for the Mediterranean. Kelloggs has been providing nutritious foods to consumers for more than 100 years and will remain committed to offering a wide range of products and meeting the consumers changing needs and tastes.

Adult students and parents who have children attending the sports sessions are encouraged to attend. It is advisable that one registers in advance. Interested persons can reserve a place by calling KMS Skolasport on tel. no 21660658/9, or by sending an e-mail to programmes@sportmalta.org.mt. Kelloggs cereal products will be distributed at the end of each session.

Original post:
Kellogg’s-sponsored Nutrition talks at KMS Skolasport

Research and Markets: Genetic Engineering – Global Outlook

Posted on by

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/719d98/genetic_engineerin) has announced the addition of the "Genetic Engineering - Global Outlook" report to their offering.

The global outlook series on Genetic Engineering provides a collection of market briefs and concise summaries of research findings. The report offers an aerial view of the industry, highlights latest developments, and discusses demand drivers, issues and concerns, and regulatory environment. Discussion on the industry's most noteworthy regional market, the US, is amply detailed with unbiased research commentary to provide the reader a rudimentary understanding of the prevailing market climate. Market discussions in the report are punctuated with fact-rich market data tables.

Regional markets elaborated upon include United States, Canada, India, China, and South Africa among others. Also included is an indexed, easy-to-refer, fact-finder directory listing the addresses, and contact details of 153 companies active in the market.

Key Topics Covered:

1. INDUSTRY OVERVIEW

2. MARKET DYNAMICS

3. ISSUES AND CONCERNS

4. REGIONAL TRENDS

5. GENETIC ENGINEERING: AN OVERVIEW

The rest is here:
Research and Markets: Genetic Engineering - Global Outlook

DNA match leads to man's arrest in 1974 Oakland slaying of teen girl

Posted on by

OAKLAND -- In what is believed to be the oldest cold case solved so far by Oakland police, a DNA match has led to special circumstance murder charges being filed against a 63-year-old ex-convict in the August 1974 fatal beating and sexual molestation of a 13-year-old East Oakland girl, authorities said Tuesday.

Curtis J. Tucker is charged with murder and the special circumstance enhancements of lewd or lascivious acts upon a child and that the killing happened during a burglary.

The victim, Julie McElhiney, a sixth grader at Sequoia Elementary School, was found about 5:40 p.m. Aug. 9, 1974, by her mother, in the bathroom of their apartment in the 3000 block of Pleitner Avenue. She had been beaten to death. Her mother told investigators she had talked to her daughter on the phone about 1 p.m. and there was no indication anything was wrong.

Tucker, a U.S. Army veteran who was arrested last Thursday at an Oakland veterans clinic, refused to talk to investigators, said Sgt. Mike Weisenberg, a patrol sergeant who works part-time in the department's cold case unit.

Weisenberg said the family did not know Tucker and had no prior contact with him. He said police are not sure of the motive.

Authorities said Tucker has a criminal record going back to the 1970s, including a felony burglary conviction in Oakland in 1972 that he went to prison for. In that case, he posed as a deliveryman and broke into a woman's downtown apartment and tried to sexually

He also has arrests in other states, including one in Washington that led to him being identified in the Oakland slaying.

The department a few years ago formed a cold case unit made up of a retired sergeant and current officers who help investigate cold cases part-time like Weisenberg. Recently an officer was assigned full-time to the unit.

Weisenberg was assigned the McElhiney case on April 2, 2010. He reviewed the evidence and found that a T-shirt Julie was wearing had semen stains on it. He requested a DNA analysis on April 22, 2010.

Because of a severe backup in the Oakland police crime lab, a possible match did not come back until last November after a nationwide DNA database search. The match with Tucker's DNA was confirmed with additional testing, as is procedure in such cases.

See the article here:
DNA match leads to man's arrest in 1974 Oakland slaying of teen girl

Posted in DNA

Coalition Wants Moratorium on 'Extreme' Synthetic Bio Businesses

Posted on by

By Matt Jones

NEW YORK (GenomeWeb News) An international advocacy coalition today called for a moratorium on the development of new synthetic organisms for commercial use while new international regulations for governing the synthetic biology sector are created to protect the environment and people from unknown perils.

The coalition said today that synbio represents "extreme genetic engineering." It said there currently is little or no governance over synthetic organisms, and private companies cannot be trusted to self-regulate and protect people and the environment from risk and harm.

"We are calling for a global moratorium on the release and commercial use of synthetic organisms until we have established a public interest research agenda, examined alternatives, developed the proper regulations, and put into place rigorous biosafety measures," Carolyn Raffensperger, executive director of the Science and Environmental Health Network, said in a statement today.

"Self-regulation of the synthetic biology industry simply won't work," added Andy Kimbrell, executive director of the International Center for Technology Assessment. "Current laws and regulations around biotechnology are outdated and inadequate to deal with the novel risks posed by synthetic biology technologies and their products."

Friends of the Earth and over 100 international groups focused on environmental, bioscience, food safety, human and consumer rights issues, and religion, said in a report published today that although the synbio market had a value of more than $1.6 billion in 2011 and could hit $10.8 billion by 2016, there has been "little or no governance of the industry or assessment of the novel risks posed by synthetic organisms."

In a conference call today unveiling the report, Jaydee Hanson, policy director at the International Center for Technology Assessment, said that the first creation of a synthetic genome and its implantation into a microbe by the J. Craig Venter Institute in 2010 "should have been a wake-up call for governments around the world, but little new oversight resulted."

"The ability to synthesize DNA and create synthetic organisms and products is far outpacing our understanding of how these novel products work in the real world. Even engineering simple organisms could have major ecological and health effects," Hanson said.

In its report, "The Principles for the Oversight of Synthetic Biology," the consortium calls for governments to take specific steps to account for a range of possible effects caused by synthetic organisms.

It calls for a moratorium on the release and commercial use of synthetic organisms, cells, or genomes, until a government research agenda has been established to study the public's interest. The moratorium also would hold while alternative approaches are considered and risk assessments are made, and international oversight and security mechanisms are developed.

Read more from the original source:
Coalition Wants Moratorium on 'Extreme' Synthetic Bio Businesses

Textbook breaks new ground in experimental biology

Posted on by

(PR NewsChannel) / March 13, 2012 / BEIJING

"New Experimental Biology" by Winpen Hann

In New Experimental Biology: Deep Structure Studies II (ISBN 1467987182), scientist Winpen Hann maps a new path for biology, pushing it beyond its current focus on molecular data and genome mapping. His book is a timely introduction to Deep Structure Theory, which introduces new concepts to explain how species physically transform themselves through evolutionary adaptation. The biology textbook reviews four decades of select experiments, which open up possibilities for new insights into brain science, genomics, artificial intelligence and chronic diseases.

The book works from the assumption that many experimental methods of modern-day biology have been pushed to their limit. New Experimental Biology looks at different paths for research that can reinvigorate the field. For instance, studies in molecular biology, biochemistry and structural biology have yielded vast universes of data.

Yet for biologists of all stripes, the question still remains of what to do with this mountain of knowledge. What theory and methods can effectively integrate the vast amounts of data and information yielded by a global community of scientists? Hanns book offers a promising answer through the experimental methods of Deep Structure Theory, which promise to reconcile biologys cell and molecular-level knowledge with an organisms behavior, movement and physiology.

Intended for scientists, professors, researchers and anyone else who wants to keep abreast of cutting-edge developments in science, New Experimental Biology is a textbook that proposes a new view of scientific research that is equally concerned with micro- and macro processes. It is a new, comprehensive vision of biology which seeks to systematize knowledge of an organisms genetic activity with the ecology in which it must ultimately thrive and reproduce.

New Experimental Biology: Deep Structure Studies II is available for sale online at Amazon.com and other channels.

About the Author: Winpen Hann is director of the Brain and Ecology Deep Structure Lab and Deep Structure Bio-science Research Co., Ltd. He is also director of the original Brain and Ecology Comparative Group. His interests include ecology, evolutionary biology and economics. Hanns other books include New Experimental Biology and The Deep Structure of Life, which he authored in his native language, Chinese.

MEDIA CONTACT Winpen Hann E-mail: Winpen@brainecology.netPhone: 0086 + 13 + 02003-9389 Website: http://www.brainecology.net

REVIEW COPIES AND INTERVIEWS AVAILABLE

Continue reading here:
Textbook breaks new ground in experimental biology

UTHSCT researchers receive five seed grants totaling $115,000

Posted on by

UTHSCT researchers receive five seed grants totaling $115,000

Five seed grants totaling $115,000 have been awarded to researchers at The University of Texas Health Science Center at Tyler. The locally raised money will help UTHSCT researchers explore new cures for serious diseases, saidSteven Idell, MD, Ph.D., UTHSCTs vice president for research.

Hong-Long Ji, Ph.D., associate professor of biochemistry, was awarded a $40,000 grant to study the relationship between abnormal genes and chronic obstructive pulmonary disease (COPD).

Usha Pendurthi, Ph.D., professor of molecular biology, received $40,000 to fund her work into how certain proteins that curb blood clotting affect the growth of cancerous tumors.

Proteins are required for the structure, function, and regulation of the bodys cells, tissues, and organs; each protein has unique functions. Hormones, enzymes, and antibodies are all examples of proteins.

Buka Samten, Ph.D., associate professor of microbiology and immunology, and Malini Madiraju, Ph.D., professor of biochemistry, were awarded $20,000 for preliminary research that could lead to a better vaccine against tuberculosis. Thats important, because TB kills more than a million people each year, according to the World Health Organization.

Anna Kurdowska, Ph.D., professor of biochemistry, received $10,000 for her research into a new way to treat acute lung injury, also known as acute respiratory distress syndrome (ARDS). And Amir Shams, Ph.D., associate professor of microbiology and immunology, received $5,000 to examine how to keep treatments for injured lungs inside those lungs.

These grants enable our scientists to pursue new and exciting research that could change our understanding of how serious diseases develop, as well as transform how we treat them. They help our researchers acquire the preliminary data they need to successfully compete for funding from the National Institutes of Health, the gold standard in biomedical research, Dr. Idell said, calling this years projects outstanding.

Funding for the seed grants comes from UTHSCs Research Council and the Texas Lung Injury Institute. Since 2002, scientists in the Center for Biomedical Research have been awarded $118.6 million in research dollars.

Continued here:
UTHSCT researchers receive five seed grants totaling $115,000

Research and Markets: Biochemistry for Sport and Exercise Metabolism

Posted on by

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/b561c1/biochemistry_for_s) has announced the addition of John Wiley and Sons Ltd's new book "Biochemistry for Sport and Exercise Metabolism" to their offering.

How do our muscles produce energy for exercise and what are the underlying biochemical principles involved? These are questions that students need to be able to answer when studying for a number of sport related degrees. This can prove to be a difficult task for those with a relatively limited scientific background. Biochemistry for Sport and Exercise Metabolism addresses this problem by placing the primary emphasis on sport, and describing the relevant biochemistry within this context.

The book opens with some basic information on the subject, including an overview of energy metabolism, some key aspects of skeletal muscle structure and function, and some simple biochemical concepts. It continues by looking at the three macromolecules which provide energy and structure to skeletal muscle - carbohydrates, lipids, and protein. The last section moves beyond biochemistry to examine key aspects of metabolism - the regulation of energy production and storage. Beginning with a chapter on basic principles of regulation of metabolism it continues by exploring how metabolism is influenced during high-intensity, prolonged, and intermittent exercise by intensity, duration, and nutrition.

Key Features:

Biochemistry for Sport and Exercise Metabolism will prove invaluable to students across a range of sport-related courses, who need to get to grips with how exercise mode, intensity, duration, training status and nutritional status can all affect the regulation of energy producing pathways and, more important, apply this understanding to develop training and nutrition programmes to maximise athletic performance.

Key Topics Covered:

For more information visit http://www.researchandmarkets.com/research/b561c1/biochemistry_for_s

Original post:
Research and Markets: Biochemistry for Sport and Exercise Metabolism

Disruptive Innovations and Unsustainable Costs Propel Life Sciences Companies Into the Behavioral Change Business

Posted on by

Quotes delayed, except where indicated otherwise. Delay times are 15 mins for NASDAQ, NYSE and Amex. See also delay times for other exchanges. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.

Fundamental company data provided by Capital IQ. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data and daily updates provided by Morningstar, Inc.

Yahoo! - ABC News Network

Read the rest here:
Disruptive Innovations and Unsustainable Costs Propel Life Sciences Companies Into the Behavioral Change Business

Two ECU grad programs ranked

Posted on by

Two graduate programs at East Carolina University have been ranked among the best in the nation according to an annual list from U.S. News & World Report.

The rehabilitation counseling program and the Brody School of Medicine were included in the magazine's 2013 listing of the best professional and graduate schools released today.

The rehabilitation counseling program in the College of Allied Health Sciences is ranked the 13th.

"Our graduates are in high demand in substance abuse, mental health and other rehabilitation settings," said Dr. Lloyd Goodwin, professor and interim chair of the Department of Rehabilitation Studies at ECU.

"Student interns are almost always offered jobs at the end of their internship and often before completion of their internship. It is rare for a graduate to not be offered a position within one month of graduation."

The Brody School of Medicine tied for 31st overall among primary care schools this year. ECU also sent the seventh-highest percentage of its graduates, 49.6 percent, into primary care residencies between 2009 and 2011. U.S. News defines primary care as family medicine, pediatrics and internal medicine.

"We are glad to be included among some very fine and well-established schools from across the country," said Dr. Paul Cunningham, dean of the medical school. "We will continue to pursue our mission to serve the citizens of North Carolina with passion and purpose."

The U.S. News guidebook of U.S. professional and graduate schools will be available on newsstands April 3.

Read more from the original source:
Two ECU grad programs ranked

Cannabis Science, Inc. Begins Pre-Production of Groundbreaking Cannabis Television Documentary

Posted on by

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--

Cannabis Science, Inc. (OTCBB:CBIS.OB - News), a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is excited to be embarking on a medical marijuana documentary project. Pre-production of this groundbreaking educational film is currently underway.

Many documentaries about marijuana have been made, typically focusing on getting high or the medicinal effects and benefits. Cannabis Science will be first documentary to focus on the science behind medicinal cannabis, including untangling the history of marijuanas reputation, the improvement it can bring to peoples daily lives, and what breakthroughs could be on the horizon for this emerging industry.

Modern science supports a long list of illnesses that cannabis can treat: Multiple Sclerosis, Cancer, Arthritis, HIV/Aids, Asthma, Alzheimer's Disease, Anti-aging, Auto Immune Disease, brain trauma (closed head injury), Crohn's Disease, chronic pain management, Diabetes, digestive illnesses, Gastro Intestinal Reflux Disease (GERD), high blood pressure, Glaucoma, Influenza, Methicillin-Resistant Staphylococcus Aureus (MRSA), Post Traumatic Stress Disorder (PTSD), Tourette Syndrome, and Irritable Bowel Syndrome (IBS), etc. The science gives a foundation for understanding the broad spectrum of benefits that can be achieved by increasing the cannabinoid activity in people suffering from so many illnesses.

Part of the science that will be explored are the various forms marijuana can take as a medication, including edibles, pills, liquids, and strips that dissolve on the tongue. The documentary will investigate how these forms are processed in the body and can reverse or minimized the effects of disease. Cannabis Science is first and foremost a patient orientated company. Therefore, patients will be interviewed, giving the audience a glimpse at the real, positive benefits the medicine provides for those with chronic illness, as opposed to the prevailing and false belief that marijuana is addictive and even harmful.

Other documentaries showcase marijuana culture, likening it to the popular view of the 1960s and marijuana use running rampant among the hippie population. Cannabis Sciences documentary, however, will show cannabis in a positive light and demonstrate that what has been, and is, taught by prohibitionists is false, and ignores modern science, history, and the voice of patients. The documentary will also focus on the co-founders of Cannabis Science, how the company is working to target critical illnesses, conducting much needed research, and is developing cannabis-based medications. The audience will hear the views of doctors who have discovered for themselves through treating patients the amazing benefits that cannabis based medicines can provide for their patients.

While the main focus of the documentary is not political, learning the truth about the science of cannabinoids will educate the public on the damage caused by prohibition. Patients whose circumstances could have drastically improved and who could have reduced the severity of their illnesses much earlier from medical marijuana will be interviewed. The film will explore the reasons behind the delay in world governments opening up to the idea that medical marijuana is a beneficial reality.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

See more here:
Cannabis Science, Inc. Begins Pre-Production of Groundbreaking Cannabis Television Documentary

‘Grey’s Anatomy’s’ Chandra Wilson to Direct her 6th Episode

Posted on by

*Greys Anatomy star Chandra Wilson will get behind the camera again for one of the remaining episodes of the current season 8.

According to The Hollywood Reporter, Wilson and co-star Kevin McKidd will each take their turn in the directors chair. Wilson, who plays Dr. Miranda Bailey, will mark her sixth time at the helm when she directs Episode 22 of Greys 24-episode season.

McKidd who plays Dr. Owen Hunt, and has already directed Episode 6 of the Shonda Rhimes drama this year, is set to take the lead again on Episode 21.

An airdate has not yet been determined for the episodes.

Greys Anatomy returns from its winter hiatus on Thursday at 9 p.m. on ABC.

Did you find this interesting? You can easily share it with friends & colleagues thanks to a wide variety of social networks like Facebook, Twitter, Digg, LinkIn, Delicious, StumbleUpon, or Tumblr... just to name a few. You can also send this via e-mail or bookmark it!

Follow this link:
‘Grey’s Anatomy’s’ Chandra Wilson to Direct her 6th Episode

Jessica Capshaw Talks Twitter Photo War With 'Grey's Anatomy' Co-Star Patrick Dempsey

Posted on by

"Grey's Anatomy" returns with an all new episode this Thursday on ABC, but during her visit to Access Hollywood Live on Tuesday, actress Jessica Capshaw revealed there is some Internet-related drama brewing behind the scenes too.

According to the actress, who plays Dr. Arizona Robbins, she and Patrick Dempsey are involved in an amusing Twitter photo war.

PLAY IT NOW: Would Patrick Dempsey Like To See Katherine Heigl Back On Greys Anatomy?

"We got into a Twitter pic war, where literally he was wielding his iPhone like it was a weapon," Jessica smiled as she told Billy Bush and Kit Hoover what's been going on with Patrick.

Jessica explained that Patrick, who recently joined Twitter, has become fond of posting photos of his cast mates, including her, in less than perfect poses.

VIEW THE PHOTOS: The Lovely Ladies Of Primetime Television

"Patrick most likes to take pictures of me in compromising positions," Jessica explained of the amusing way they've been spending their down time on set. "[Like] when you're in the middle of taking a bite of a muffin, making a sun [squinting] face, doing something that's just not attractive."

Now, for all of Twitter to see, there are a host of unapproved photos circulating of Jessica and some of her fellow "Grey's" co-stars.

"He doesn't ask us [before posting]. We live in this world where it's like, it'd be nice if someone said, 'Hey! I just took this picture, I'm gonna Tweet it now," she explained.

VIEW THE PHOTOS: Primetime Hunks

Original post:
Jessica Capshaw Talks Twitter Photo War With 'Grey's Anatomy' Co-Star Patrick Dempsey

WSU venturing into pharmacogenomics – Tue, 13 Mar 2012 PST

Posted on by

March 13, 2012 in City Researchers wooed to organize $15 million researchcenter

The HSSA was established several years ago to capture some of the local-option sales taxes collected in the Spokane area to help pay for projects designed to create a thriving research cluster in thearea.

Washington State University is recruiting two genetics researchers to its Spokane campus to launch a $15 million research enterprise that will add 135 pharmaceuticalscientists.

Its a bold research and job-creation effort announced Monday that relies in part on leveraging a $1.2 million investment of local tax dollars with federal, state and privatefunds.

These are people and projects that can be a real catalyst for Spokane, said Susan Ashe, acting executive director of the Health Sciences & Services Authority of SpokaneCounty.

Called the HSSA, the authority was established several years ago to capture a sliver of the local-option sales taxes collected in the Spokane area to help pay for projects designed to create a thriving research clusterhere.

If successful, the projects will turn into either sustained research facilities that create jobs, or they will produce ideas or goods that can becommercialized.

Philip Lazarus, a professor and researcher at Penn State Universitys College of Medicine, has been offered a position to erect a new academic and research program at WSU, a rare opportunity that WSU is dangling as a recruitment tool along with a generous financial package. The HSSA is contributing $500,000 over two years to help bring Lazarus to Spokane and set up hisprogram.

This is pretty exciting stuff. An opportunity in academic research to really create something with your stamp on it, said Gary Pollack, WSU vice provost for healthsciences.

More:
WSU venturing into pharmacogenomics - Tue, 13 Mar 2012 PST

Crocus and Kintech Sign Agreement to Perform Nanotechnology R&D in Russia

Posted on by

SANTA CLARA, Calif., March 13, 2012 /PRNewswire/ -- Crocus Technology, a leading developer of magnetically enhanced semiconductors, today announced that it has signed a research and development agreement with Kintech Lab, a leading researchcompany in Russia, specializing in the development of advanced methodologies and multi-scale software tools for modeling complex electronics and other physical phenomena.

Under the terms of the agreement, Kintech Lab will develop a modeling platform and perform complete physical simulation of Crocus' TAS MLU memory cell.The simulation results will provide deeper understanding of the nano-scale performance of the TAS MLU cell and enable Crocus to optimize materials and processing for enhanced functionality and reliability.

"Crocus is delighted to collaborate with Kintech Lab on advanced modeling of our MLU technology," said Ken MacKay, Crocus' director of Magnetic Technology Engineering. "Kintech's world-class expertise in physics and modeling will be instrumental to Crocus as we migrate our process technologies to state-of-the-art lithography."

In May 2011, Crocus announced that it will invest over $5 million into Russian research organizations to develop advanced technology and manufacturing solutions. This partnership with Kintech represents the first step towards achieving that objective, as set forth in Crocus' agreement with RUSNANO to develop advanced magnetic nanotechnology manufacturing and science in Russia.

"This initiative with Crocus is setting the foundation for model-based advanced nano-magnetic research in Russia," said Boris Potapkin, chief executive officer of Kintech Laboratory. "We look forward to working with Crocus on solving problems essential to the deployment of leading edge technologies."

About CrocusCrocus is a leading developer of magnetic semiconductor technology for dense, non-volatile, high-speed, scalable chip solutions used in general and special purpose applications. The company's Magnetic Logic Unit (MLU) architecture, featuring a revolutionary self-reference technique, is a scalable evolution of Crocus' patented Thermally Assisted Switching (TAS) technology. MLU enables practical implementation of advanced magnetic logic and memory capabilities. Crocus' first generation magnetic technology was originally conceived at the Grenoble, France-based Spintec, a world leading magnetic research laboratory affiliated with two leading French labs, CEA and CNRS. It was further developed for production at SVTC in California and is in its final phase of implementation at Tower Jazz semiconductor. In October 2011, Crocus announced a joint development agreement with IBM to further advance the technology, focusing on advanced development of the MLU architecture. Crocus' technology is covered by a comprehensive patent portfolio. In May 2011, Crocus and RUSNANO formed a joint venture, Crocus Nano Electronics (CNE), to build and operate an advanced manufacturing facility for magnetic semiconductors. Find Crocus at: http://www.crocus-technology.com

About Kintech LabKintech Lab develops and implements integrated computer simulation software and information systems for first principles-based predictive multi-scale modeling and analysis of the properties of new processes, materials and devices. Kintech Lab carries out scientific research projects in the fields of combustion and plasma technologies, catalysis, advanced energy systems including fuel and solar cells, batteries, light sources, nanotechnologies and new materials. In 2011, Kintech Lab obtained status as a Skolkovo resident, and in January 2012 was awarded with a $1.3 million grant supporting a projected titled, 'Technique of predictive multi-scale modeling and mechanistic development of processes for efficient power engineering, chemical industry and the design of new materials.' For more information about Kintech Lab, visit http://www.kintechlab.com.

Read the rest here:
Crocus and Kintech Sign Agreement to Perform Nanotechnology R&D in Russia

Nanotechnology Market Forecast to 2014

Posted on by

NEW YORK, March 13, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Nanotechnology Market Forecast to 2014

http://www.reportlinker.com/p0118193/Nanotechnology-Market-Forecast-to-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Nanotechnology

In the coming years, nanotechnology is set to play a pivotal role in various industry segments. The evolving technology has already influenced a large number of industrial segments, and the economic activity generated from it has been high in magnitude and wide in scope. The nanotechnology-based products, which have had a huge impact on almost each industrial sector, are now entering the consumer market in a big way. As per the findings of our latest report, increased applications of the technology in sectors like electronics, cosmetics, and defense, would propel the growth of the global nanotechnology market, which is anticipated to expand at a CAGR of about 19% during 2011-2014.

According to "Nanotechnology Market Forecast to 2014", electronic companies are finding new ways of incorporating nanotechnology into consumer products like music systems and mobile phones in order to improve their processing capabilities. Similarly, the technology could help improve cosmetics by changing their physical properties. We also observed that the use of nanotechnology in defense technologies provides enhanced performance at lower cost. Besides, the budding technology has revolutionalized dental care as it decreases the healing time and improves the Osseo-integration during dental implant. Our report discusses in detail these application areas and the key market trends.

Though nanomaterials would continue to dominate the nanotechnology market in the coming years, nano devices, comprising nanolithographic tools for manufacturing the next generation semi-conductors, are estimated to grow at a much faster rate than nanomaterials in near future. The crucial country-level analysis, included in the comprehensive research, identified that the US is the world's most prominent nanotechnology market and will continue to enjoy the biggest pie of the global industry in the years to come, despite developing economies like China, Korea, India, and Brazil investing huge sums in the nanotechnology R&D. Our report elaborates the application areas and regulatory environment relating to nanotechnology in these countries, along with the patent analysis.

With a view to providing a balanced outlook of the global nanotechnology market to clients, our report also includes the profiles of key industry players, like Altair, Nanophase Tech and Nanosys, among others. Overall, the objective of the study is to help clients understand the prospects of the industry, and make sound investment decisions in view of those.

1. Analyst View2. Research Methodology3. Nanotechnology - An Introduction4. Key Market Trends and Developments4.1 Nanotechnology: The New Buzz Word in Dental Care4.2 Nano-sand: Preventing Water Loss4.3 NanoRobots: Boon for Medical and Other Industries5. Nanotechnology Market Overview6. Industry Performance: Current and Future Outlook6.1 By R&D Funding6.1.1 Government6.1.2 Corporate6.1.3 Venture Capital6.2 By Major Applications6.2.1 Electronics: Potential of Solid State Nano-electronics6.2.1.1 Nanocircuits6.2.1.2 Nanowires6.2.1.3 NanoSensors6.2.2 Energy: Application of Nanotechnology in Value Added Chain6.2.2.1 Energy Source6.2.2.2 Energy Conversion6.2.2.3 Energy Storage6.2.2.4 Energy Distribution6.2.3 Nano-Cosmetics: Beyond Skin Deep6.2.3.1 Skin Care6.2.3.2 Hair Care6.2.3.3 Perfumes6.2.4 Biomedical: Nanotechnology Developing Medical Application6.2.4.1 Drug Delivery6.2.4.2 Therapeutics6.2.4.3 Medical Materials & Implants6.2.4.4 Analytical Tools & Instruments6.2.4.5 Diagnostics6.2.5 Defense: Nanotechnology Bringing Innovative Opportunities6.2.5.1 Military Vehicles6.2.5.2 Aeronautics6.2.5.3 Satellites7. Country Level Analysis7.1 US7.2 Brazil7.3 Germany7.4 France7.5 UK7.6 Ireland7.7 Russia7.8 Japan7.9 South Korea7.10 Taiwan7.11 China7.12 India7.13 Australia8. Patents Analysis9. Competitive Landscape9.1 Altair Nanotechnologies Inc.9.2 Nanophase Technologies Corporation9.3 Nanosys, Inc.9.4 Unidym, Inc.9.5 Ablynx9.6 NanoScale Materials, Inc.9.7 Zyvex Corporation9.8 Acusphere, Inc.

List of Figures:

Figure 5-1: Global - Nanotechnology Market (Billion US$), 2009-2014Figure 5-2: Global - Nanotechnology Market by Component (%), 2011Figure 5-3: Global - Forecast for Nanotechnology Market by Component (%), 2014Figure 5-4: Global - Nanotechnology Market by Region (%), 2009Figure 6-1: Global - Nanotechnology Funding (Billion US$), 2008 & 2009Figure 6-2: Global - Nanotechnology Funding by Source (%), 2009Figure 6-3: Global - Government Funding in Nanotechnology (Billion US$), 2008 & 2009Figure 6-4: Global - Corporate Funding in Nanotechnology (Billion US$), 2008 & 2009Figure 6-5: Global - Corporate Funding in Nanotechnology by Leading Countries (Billion US$), 2008Figure 6-6: Global - Venture Capital Funding in Nanotechnology (Billion US$), 2008 & 2009Figure 6-7: Global - Venture Capital Funding in Nanotechnology by Region (%), 2009Figure 6-8: Global - Use of Nanoparticles in Electronic Applications (Million US$), 2009-2014Figure 6-9: Global - Use of Nanoparticles in Energy Applications (Million US$), 2009-2014Figure 6-10: Global - Use of Nanoparticles in Cosmetic Applications (Million US$), 2009-2014Figure 6-11: Global - Use of Nanoparticles in Biomedical Applications (Million US$), 2009-2014Figure 6-12: Global - Share of Defense in Nanotechnology Market (2007 & 2015)Figure 7-1: US - Funding in Nanotechnology (Billion US$), 2008 & 2009Figure 7-2: US - Federal Funding in Nanotechnology (Billion US$), 2010-2012Figure 7-3: US - Forecast for Proposed Federal Funding by Category (%), 2012Figure 7-4: US - Nanotechnology-enabled Products Market (Billion US$), 2007 & 2009Figure 7-5: Brazil - Government Investment in Nanotechnology (Million US$), 2004-2009Figure 7-6: Brazil - Share of Public and Private Funding in Nanotechnology (2008)Figure 7-7: Germany - Funding in Nanotechnology (Million US$), 2009-2012Figure 7-8: Germany - Forecast for Share of Active Participants in Nanotechnology (2012)Figure 7-9: UK - Funding in Nanotechnology (Million GBP), FY 2010 & FY 2011Figure 7-10: Ireland - Share of Government Funding by Activity (2001-2009 & 2010-2014)Figure 7-11: Russia - Investment in Nanotechnology (Billion US$), 2009-2015Figure 7-12: Russia - Nano-enabled Products Market (Billion US$), 2009-2015Figure 7-13: Russia - Nano-enabled Products Export (Billion US$), 2009-2015Figure 7-14: Russia - Forecast for Share in Global Nano-industry Products Market (2014)Figure 7-15: Japan - Public Funding in Nanotechnology/Materials (Billion JPY), FY 2007 to FY 2010Figure 7-16: Japan - Government Funded Projects (2001 to 2014)Figure 7-17: South Korea - Government Investment in Nanotechnology (Billion KRW), FY 2008 & FY 2009Figure 7-18: South Korea - Investment in Nanotechnology by Segment (%), 2009Figure 7-19: South Korea - Investment in Nanotechnology by Ministry (Billion KRW), 2009Figure 7-20: South Korea - Distribution of Nanotech Companies by Technological Field (%), 2009Figure 7-21: South Korea - Distribution of Nanotech Products by Technological Field (%), 2004 to 2008Figure 7-22: South Korea - Distribution of Commercialization Success by Technological Field (%), 2008Figure 7-23: South Korea - Location of Nanotechnology Development Infrastructure (2009)Figure 7-24: Taiwan - Allocation of Funds in NNP, Phase I (%), 2003 to 2008Figure 7-25: Taiwan - Allocation of Funds in NNP, Phase II (%), 2009 to 2014Figure 7-26: Taiwan - Nanotechnology Industry Output (Billion US$), 2008 & 2010Figure 7-27: China - Funding in Nanotechnology (Million US$), 2009 & 2013Figure 7-28: China - Nanotechnology Market (Billion CNY), 2008 & 2013

Excerpt from:
Nanotechnology Market Forecast to 2014

3D printer with nano-precision sets world record

Posted on by

Summary: Researchers at the Vienna University of Technology have developed a method for fabricating intricately structured sculptures as tiny as a grain of sand in record speed.

Using a technique known as two-photon lithography, Austrian researchers have developed a high-precision 3D printer capable of producing nanometer sized objects in the shape of race cars, cathedrals, and bridges in a matter of minutes.

The high-precision-3D-printer at TU Vienna is purportedly orders of magnitude faster than similar devices, and opens up new areas of applications, such as in medicine.

The super fast nano-printer uses a liquid resin, which is hardened at precisely the correct spots by a focused laser beam. The focal point of the laser beam is guided through the resin by movable mirrors and leaves behind a hardened line of solid polymer, just a few hundred nanometers wide. The result is a detailed sculpture measuring a couple hundred of micrometers in length.

Until now, this technique used to be quite slow, says Professor Jrgen Stampfl from the Institute of Materials Science and Technology at the TU Vienna. The printing speed used to be measured in millimeters per second our device can do five meters in one second. In two-photon lithography, this is a world record.

The scientists at TU Vienna are now developing bio-compatible resins for medical applications that can be used to create scaffolds to which living cells can attach themselves for the systematic creation of biological tissues. The 3D printer could also be used to create tailor-made components for biomedical technology or nanotechnology.

The video below shows the 3D-printing process in real time. The very fast control mechanism connected to the laser beam produces 100 layers, consisting of approximately 200 single lines each, in four minutes.

Source: Vienna University of Technology

Related

Read more here:
3D printer with nano-precision sets world record